Clinical Trial Update: Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) [Phase 2]

View source ↗

Summary

Phase 2 trial (PRESERVE 4) evaluating trilaciclib with docetaxel in metastatic non-small cell lung cancer was terminated with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non Small Cell Lung Cancer

Drugs mentioned

• trilaciclib (trilaciclib)

Snippet

Sponsor: G1 Therapeutics, Inc. | Conditions: Metastatic Non-Small Cell Lung Cancer, NSCLC | Phase 2 | Status: TERMINATED | Results posted: 2023-04-14